forbes.com — Emmanuel (Ed) Baetge, chief scientific officer at San Diego biotech Novocell, may be closer than anyone else to using embryonic stem cells to cure Type 1 diabetes. His work shows the immense promise of stem cell transplants—and the huge hurdles that stand in the way of their becoming a medical reality.